“Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials with VP-102 CAMP-1 and CAMP-2” (2021) SKIN The Journal of Cutaneous Medicine, 5(6), p. s92. doi:10.25251/skin.5.supp.92.